✦ LIBER ✦

Bortezomib Plus Thalidomide for Newly Diagnosed Multiple Myeloma in China

✍ Scribed by Shi-Lun Chen; Bin Jiang; Lu-Gui Qiu; Li Yu; Yu-Ping Zhong; Wen Gao

Publisher: Wiley (John Wiley & Sons)
Year: 2010
Tongue: English
Weight: 126 KB
Volume: 293
Category: Article
ISSN: 1932-8486
DOI: 10.1002/ar.21218

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bortezomib in combination with dexametha

Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience

✍ Weiyan Zheng; Guoqing Wei; Xiujin Ye; Jingsong He; Li Li; Wenjun Wu; Jimin Shi; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 245 KB

## Objective: Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (mm) with an overall response rate of 92% and a cr rate of 18% (alexanian et al, hematology 2007;12(3):235-9), but this regimen has not been tested in the chinese patients. we re

Bortezomib plus intermediate-dose dexame

Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: A Chinese experience

✍ Hongfeng Guo; Xin Zhou; Yuanqiang Jiang; Guohua Yang; Chao Sun; Yun Zhuang; Hong 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 2 views

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

Cyclophosphamide plus dexamethasone is a

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame

Circulating angiopoietin-1 to angiopoiet

Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents

✍ Evangelos Terpos; Konstantinos Anargyrou; Eirini Katodritou; Efstathios Kastriti 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 456 KB 👁 1 views

## Abstract The circulating levels of several angiogenic cytokines [angiopoietin‐1 (Ang‐1), angiopoietin‐2 (Ang‐2), vascular endothelial growth factor (VEGF), angiogenin and basic fibroblast growth factor (bFGF)] were evaluated in 174 consecutive patients with newly diagnosed, symptomatic, multiple